Form 4: Syndax Pharmaceuticals Director Huber Martin H. Jr. Acquires 5,000 Shares
SEC Form 4 Filing
Director Huber Martin H. Jr. of Syndax Pharmaceuticals Inc. purchased 5,000 shares of common stock at $8.99 per share on May 19, 2025, and now owns 79,000 shares.
Summary
- On May 19, 2025, Huber Martin H. Jr., a director of Syndax Pharmaceuticals Inc., acquired 5,000 shares of common stock.
- The purchase price was $8.99 per share.
- Following the transaction, Huber Martin H. Jr. beneficially owns 79,000 shares of Syndax Pharmaceuticals Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction report. The director's purchase is a mildly positive signal, but not significantly impactful on its own.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment due to the director's increased investment in the company.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of transaction: Huber Martin H. Jr. purchased 5,000 shares of Syndax Pharmaceuticals Inc. common stock. |
Keywords
Syndax Pharmaceuticals, Director, Stock Acquisition, Form 4, Beneficial Ownership, SNDX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.